- Global Pharma News & Resources

M1 Kliniken AG publishes preliminary figures for the 2020 financial year: revenue rises to € 160 million; net profit for the year amounts to € 7.4 million.

DGAP-News: M1 Kliniken AG / Key word(s): Preliminary Results/Miscellaneous
27.04.2021 / 11:00
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG publishes preliminary figures for the 2020 financial year: revenue rises to € 160 million; net profit for the year amounts to € 7.4 million

- Group turnover rises by more than 100 % to 159.6 million euros

- Consolidated net income falls by 24 % to 7.4 million euros due to the pandemic

- Outlook for 2021: restart of expansion and promotion of private label business

Berlin, 27 April 2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the financial year 2020. In the past financial year, the M1 Group was able to maintain its market leadership in Germany in the field of aesthetic medicine and - despite considerable burdens due to pandemic-related closures of clinics - generated a clearly positive operating result. In addition, the acquisition of Haemato AG laid the foundation for the development and expansion of the private label business.

In the 2020 financial year, the M1 Group was able to increase consolidated group sales by more than 100% to 159.6 million euros (previous year: 77.2 million euros). This includes sales of Haemato AG for the period Aug. - Dec. 2020 in the amount of 102.8 million euros. The closure of the clinic and practice operations in spring 2020 locked two full months of revenue and the occupancy rates of the specialist centres were also "below potential" in Q4 2020 due to the pandemic. However, revenue in the "Beauty" segment fell by only 7% year-on-year to €37.4 million (previous year: €40.3 million). Including the international locations, the group performed almost 270,000 treatments.

The operating profit 2020 (EBIT) amounted to 4.4 million euros (previous year 7.9 million euros). In this context, M1 recorded an operating loss of 1.9 million euros in its foreign beauty subsidiaries - due to very long lock-down periods (especially UK and Australia) and the activities in most foreign subsidiaries still in the early stages. Haemato AG achieved an operating result (EBIT) of 1.6 million euros for the full year 2020.
The financial result fell from €4.8 million (2019) to €4.4 million. This includes income of 3.6 million euros from the initial consolidation of Haemato AG.
Earnings before taxes fell from 12.7 million euros to 8.8 million euros. Consolidated net income for the year fell to 7.4 million euros (previous year: 9.7 million euros). Earnings per share amounted to 0.37 euros (previous year: 0.56 euros).

At 61%, the equity ratio remains at a very high level (previous year: 74 %). Due to the full consolidation of Haemato AG as of 31 December 2020, higher bank liabilities are included and reduce the equity ratio compared to the previous year. Cash flow amounted to 12.9 million euros.

According to current planning, the company expects to restart its growth course in the beauty segment for the full year 2021, whereby the specific timing of the expansion will be largely determined by the development of the Corona pandemic. To date, three new specialist centres have already been opened in Germany (Kiel, Erfurt, Freiburg), and two more openings are being prepared until mid 2021. Abroad, all specialist centres are open to the public again since 12 April 2021. Activities to open further international specialist centres have been resumed. By the end of 2024, a total of 100 specialist centres for aesthetic medicine are targetted. The first interim goal is a total of 50 specialist centres by the end of 2021.
The subsidiary Haemato AG intends to continue its economic recovery course in 2021. In March 2021, the company received a special approval in accordance with § 11 para. 1 MPG from the Federal Institute for Drugs and Medical Devices (BfArM) for the antigen rapid test for self-testing of laypersons. The current Corona strategy of the Federal Government and the Federal States, which has made the submission of negative Covid tests obligatory for many areas of public life and the economy, currently leads us to expect a high demand for these rapid tests.

At the beginning of the Corona pandemic in the first half of 2020, M1 Kliniken AG signed a KfW-backed entrepreneurial loan to secure the Group's liquidity. In this context the distribution profits to the shareholders is blocked. The Board of Management will therefore propose to the Annual General Meeting to carry forward the balance sheet profit in full to new account.

The Annual Report 2020 of M1 Kliniken AG will be published on 27 May 2021.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik for plastic und aesthetic surgery in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia.

After the acquisition of Haemato AG in 2020 and the bundeling of all trade and product development activities M1 is now pushing forward the private label product business.


M1 Kliniken AG
Dr. Walter von Horstig, Management Board
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14

27.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1188461

End of News DGAP News Service

Editor Details

Last Updated: 27-Apr-2021